
|Articles|August 15, 2004
Drug and prosthetic therapies for ED step forward
At the 2004 AUA annual meeting, researchers reported that daily administration of a phosphodiesterase type-5 inhibitor improves chances of recovery from post-prostatectomy erectile dysfunction-good news about a difficult-to-treat patient population. The bad news was a finding that herbal ED treatments purchased over the Internet are often ineffective, potentially dangerous, and occasionally tainted with active, unlabeled PDE-5 inhibitors.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
2
NDV-01 produces robust 9-month results in high-risk NMIBC
3
Choosing salvage therapy after prostate cancer focal ablation
4
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
5


















